{"nctId":"NCT00686517","briefTitle":"Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552/MK-4031-137)","startDateStruct":{"date":"2003-12"},"conditions":["Hepatitis C"],"count":130,"armGroups":[{"label":"PEG-IFN 24","type":"EXPERIMENTAL","interventionNames":["Biological: Pegylated interferon alfa-2b"]},{"label":"PEG-IFN 12","type":"EXPERIMENTAL","interventionNames":["Biological: Pegylated interferon alfa-2b"]},{"label":"PEG-IFN + RVB 12","type":"EXPERIMENTAL","interventionNames":["Biological: Pegylated interferon alfa-2b","Drug: Ribavirin"]}],"interventions":[{"name":"Pegylated interferon alfa-2b","otherNames":["SCH 54031, PegIntron"]},{"name":"Ribavirin","otherNames":["SCH 18908, Rebetol"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosed with acute hepatitis C virus (HCV).\n* Normal and Elevated serum alanine transferase (ALT) levels\n* Positive serum HCV-RNA.\n* Aged between 18 and 65 years.\n* Negative urine or serum pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of the drug. Additionally, all fertile males with partners of childbearing age and females must be using reliable contraception during the study and additionally for participants treated with ribavirin, for 6 months (for woman) and 7 months (for man and his partner) after treatment completion\n\nExclusion Criteria:\n\n* Liver disease unrelated to HCV infection\n* Hemoglobin (Hgb) \\<12g/dL in women and \\<13g/dL in men; white blood cells (WBC) \\<3,000/uL; platelets (PLTs) \\<100,000/ul\n* Women with ongoing pregnancy or who are breast feeding\n* History of severe psychiatric disease, especially depression\n* History of neurologic disease, especially epilepsy\n* History or evidence of symptoms of severe cardiac, gastrointestinal and kidney disease\n* Positive anti-Human Immunodeficiency Virus (HIV) antibodies\n* Positive anti-nuclear antibodies (ANA) and/or Anti-Smooth Muscle Antibody (ASMA) (\\>1/80)\n* Positive Hepatitis B surface antigen (HBsAg)\n* History of having received any systemic anti-neoplastic or immunomodulatory treatment in the previous 6 months\n* History or other evidence of severe illness or any other conditions which would make the participants, in the opinion of investigator, unsuitable for the study (active drug addict except those under methadone treatment, thalassemic, dyalized included)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Sustained Response (SR) at the End of the 6-month Follow-up Period","description":"SR was defined as serum Hepatitis C Virus (HCV RNA) level at the end of 6-month follow-up below 15 IU/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"20","spread":null},{"groupId":"OG002","value":"21","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response at the End of Treatment Follow-up (ETR)","description":"ETR was achieved if serum HCV RNA level at the end of 12 or 24 weeks\n\ntreatment (depending on treatment arm) was \\<15 IU/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"28","spread":null},{"groupId":"OG002","value":"27","spread":null}]}]}]},{"type":"SECONDARY","title":"Virologic Response at 12 Months Post-treatment Follow-up (Long-term Response, [LTR]).","description":"LTR was obtained if serum HCV RNA level at the end of 12-month follow-up was \\<15 IU/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"19","spread":null},{"groupId":"OG002","value":"19","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Presenting With Alanine Transferase (ALT) Level Normalization","description":"ALT normalization was used as a measure of biochemical response to treatment. ALT levels were assessed at each study visit by the local laboratory, and efficacy measurements at the end of treatment, at 6 and 12 months post treatment follow-up were reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"31","spread":null},{"groupId":"OG002","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"27","spread":null},{"groupId":"OG002","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"23","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Rapid Virologic Response (RVR)","description":"Participants were considered to have RVR if serum HCV RNA level at 2 or 4\n\nweeks of treatment was below the cut off value of the referring local\n\nlaboratory of each participating site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"35","spread":null},{"groupId":"OG002","value":"34","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Peripheral Blood Mononuclear Cells (PBMCs)","description":"Cellular Differentiation Cluster Antigen 8-Positive (CD8+) PBMCs were measured at randomization, Treatment Weeks 2, 4, 8, and 12.","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":43},"commonTop":["Leukopenia","Pyrexia","Granulocytopenia","Arthralgia","Headache"]}}}